Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VesiculoVax RSV vaccine
- Development stage
- Preclinical
- Lead developer
- Auro Vaccines
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intranasal, Subcutaneous
01
Overview
VesiculoVax RSV vaccine is a preclinical-stage viral vector vaccine being developed by Auro Vaccines for the prevention of respiratory syncytial virus (RSV) infection. The vaccine utilizes the VesiculoVax™ platform, which employs an attenuated, replication-competent vesicular stomatitis virus (VSV) vector to deliver RSV surface glycoproteins (F and G proteins) in their authentic form. This approach is designed to stimulate the production of potent neutralizing antibodies and protective cellular immune responses. The vaccine is part of the broader PBS Vax™ platform, which combines DNA vaccine priming with VesiculoVax™ viral vector boosting to enhance immunogenicity and efficacy.
- Other names
- VesiculoVax RSV
02
Targets
RSV F (Respiratory syncytial virus fusion protein)RSV G (Respiratory syncytial virus attachment glycoprotein)
Beyond the preview
Go deeper on VesiculoVax RSV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VesiculoVax RSV vaccine.